GleamWall
中文EN

NRIX Nurix Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1549595 · Fiscal year ends 11/30

Financial factors as of 2026-08-31 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY738.8%
TTM net income YoY220.5%
TTM EPS YoY181.8%
Revenue 3-yr CAGR117.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin41.3%
Net margin42.0%
FCF margin52.7%
EBITDA margin42.5%

Returns

ROE44.0%
ROA34.3%
ROIC (approx.)84.5%
Asset turnover0.82x

Leverage & solvency

Liabilities / assets19.0%
Debt / equity0.00x
Current ratio8.44x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.29x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue1.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-11-30FY20242024-11-30
Income statement
Revenue$83.98M$54.55M
R&D expense$316.90M$221.63M
SG&A expense$52.74M$45.94M
Operating income-$285.67M-$213.03M
Pretax income-$263.70M-$193.30M
Income tax$760,000$270,000
Net income-$264.46M-$193.57M
EBITDA-$276.93M-$203.71M
EPS (basic)-3.05-2.88
EPS (diluted)-3.05-2.88
Dividends declared per share0.000.00
Weighted avg. shares (diluted)86.67M67.12M
Balance sheet
Cash & equivalents$246.96M$110.90M
Receivables$0$0
Current assets$606.82M$619.39M
PP&E, net$22.49M$17.76M
Total assets$688.13M$669.34M
Current liabilities$86.47M$95.85M
Total liabilities$149.39M$142.35M
Shareholders' equity$538.75M$526.99M
Shares outstanding101.81M75.87M
Cash flow statement
Operating cash flow-$249.47M-$172.58M
Capital expenditure$14.00M$9.27M
Free cash flow-$263.47M-$181.86M
Investing cash flow$147.85M-$257.71M
Financing cash flow$238.64M$485.67M
Depreciation & amortization$8.74M$9.32M
Stock-based compensation$37.97M$33.93M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.